Loading
Life sciences · Journal article
Pirogov Russian Journal of Surgery · September 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Drug-induced lung disease (DILD) is a significant clinical problem in the treatment of cancer patients, especially with widespread introduction of novel anticancer agents—immune checkpoint inhibitors and targeted therapies. The incidence of DILD in clinical practice and diversity of radiological manifestations are increasing. It is crucial to determine whether new clinical and imaging findings in these patients are due to disease progression, infection, pulmonary edema, or drug exposure, as this changes patient management. Although the diagnosis of DILD is usually established by excluding other possible causes, radiologists, oncologists, thoracic surgeons, and radiotherapists should be familiar with appropriate imaging patterns. This article provides an overview of the key radiological manifestations of DILD in patients with non-small cell lung cancer (NSCLC) with emphasis on novel therapeutic agents, and presents three clinical observations demonstrating different variants of drug-induced pneumonitis.